-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SOM-401 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SOM-401 in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SOM-401 in Diabetic Macular Edema Drug Details: SOM-401 (kamuvudine-8, K8)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Octreotide LA in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Octreotide LA in Neuroendocrine Tumors report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Octreotide LA in Neuroendocrine Tumors Drug Details: Octreotide long-acting (CAM-2029)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Mantle Cell Lymphoma Drug Details: Lisocabtagene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-1887 in Geographic Atrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-1887 in Geographic Atrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-1887 in Geographic Atrophy Drug Details: JNJ-1887 (HMR-59) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amivantamab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Amivantamab-vmjw...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8543 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8543 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-8543 in Follicular Lymphoma Drug Details: JNJ-80948543 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erdafitinib in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erdafitinib in Squamous Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erdafitinib in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erdafitinib in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erdafitinib in Non-Hodgkin Lymphoma Drug Details: Erdafitinib (Balversa, Erfandel) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosnodenvir in Dengue Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosnodenvir in Dengue Fever report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosnodenvir in Dengue Fever Drug Details: Mosnodenvir (JNJ-1802) is under development...